All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Investigators Set Sights on Resistance Following Establishment of Frontline RET Inhibition in RET-Altered NSCLC

July 29th 2022

With two highly selective and active RET inhibitors approved for use in patients with metastatic RET alteration–positive non–small cell lung cancer, the dilemma is not determining which agent to select but ensuring that next-generation sequencing is done up front and in the presence of acquired resistance.

Oral SERDs Could Fulfill Unmet Need in ESR1-Mutant, ER-Positive Breast Cancer

July 29th 2022

Aditya Bardia, MD, MPH, discusses recent and ongoing trials evaluating oral SERDs in estrogen receptor–positive breast cancer, the effect of ESR1 mutations on treatment efficacy, and how the use of ctDNA continues to evolve across the breast cancer space.

HER2-Mutated NSCLC Treatment Evolves From Mainstay TKIs to Novel ADCs and Beyond

July 29th 2022

Antibody-drug conjugates have demonstrated substantial activity in patients with HER2-mutated non–small cell lung cancer, with fam-trastuzumab deruxtecan-nxki showcasing the strongest response rate and progression-free survival benefit to date.

AHN Cancer Institute Recruit Brings Unique Expertise in Benefits of Exercise and Nutrition for Improving Cancer Treatment Outcomes

July 29th 2022

Colin Champ, MD, to lead AHN exercise oncology program at AGH Suburban Campus in Bellevue.

Fixed-Duration Venetoclax/Obinutuzumab Provides Robust PFS Benefit in Untreated CLL

July 29th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow-up data of the phase 3 CLL14 trial and emphasized the importance of fixed-duration treatments in high-risk patients with chronic lymphocytic leukemia.

Addressing Disparities in Lung Cancer Begins With Accountability

July 28th 2022

Narjust Florez (Duma), MD, discusses the alarming regularity of disparities in lung cancer care, the elements that perpetuate them, and ways to address them on an individual and institutional level.

Value of Biomarkers for Immunotherapy in Advanced NSCLC Continue to Evolve

July 28th 2022

Traditional predictive biomarkers for the efficacy of peri-operative immunotherapy for patients with advanced non–small cell lung cancer, such as PD-L1 expression, still hold value but newer biomarker candidates such as minimal residual disease are starting to make an impact.

Pathology Expert Unpacks the Future Role MPR and pCR in Neoadjuvant NSCLC Treatment

July 28th 2022

Ignacio I. Wistuba, MD, explains how major pathological response and pathological complete response should be interpreted and their role as clinical end points.

MRD Status Alone Is Not Necessarily Predictive of Response to Immunotherapy in NSCLC

July 28th 2022

Thought minimal residual disease can serve as an indicator for poor outcomes for patients with non–small cell lung cancer, it is not necessarily a predictor of response to immunotherapy.

Pre-NDA Meeting Held With FDA to Discuss Repotrectinib for ROS1+ Advanced NSCLC

July 28th 2022

A pre–new drug application meeting was held with representatives from Turning Point Therapeutics, Inc. and the FDA to discuss repotrectinib as a potential therapeutic option for patients with ROS1-positive advanced non–small cell lung cancer.

PC14586 Shows Preliminary Activity, Safety in p53 Y220C–Mutant Solid Tumors

July 28th 2022

The first-in-class p53 reactivator, PC14586, induced a response in approximately 1 of 4 patients with advanced solid tumors harboring p53 Y220C mutations and showcased an acceptable safety profile consisting primarily of grade 1 and 2 events.

Sylvester Experts Explain the Most Promising Advances in Cancer Research and Treatment Presented at ASCO 2022

July 28th 2022

Cancer experts at the Sylvester Comprehensive Cancer Center: Annual Oncology Update shared important progress across a wide range of cancers — prostate cancer, breast cancer, colon cancer, and more — that was presented at the American Society of Clinical Oncology 2022 Annual Meeting, the largest gathering of cancer clinicians and scientists in the United States.

Novel Agents Needed to Expand Treatment Options for Patients With High-Risk MDS

July 28th 2022

Dan Pollyea, MD, MS, discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm.

Low-Dose Belantamab Mafodotin/Nirogacestat Demonstrates Encouraging Clinical Activity in R/R Myeloma

July 27th 2022

Nirogacestat plus belantamab mafodotin induced promising responses with manageable safety for patients with relapsed/refractory multiple myeloma.

Neoadjuvant mFOLFIRINOX Produces Favorable OS Results Without Radiation in Borderline Resectable Pancreatic Cancer

July 27th 2022

Neoadjuvant mFOLFIRINOX induced favorable overall survival results for patients with borderline resectable pancreatic ductal adenocarcinoma when administered prior to pancreatectomy, though neoadjuvant mFOLFIRINOX followed by hypofractionated radiation therapy did not prove to be similarly effective.

Ibrutinib Plus Obinutuzumab Elicits Intriguing Survival Benefits in Relapsed/Refractory CLL

July 27th 2022

Christine Ryan, MD, discussed the evaluation of safety and efficacy of ibrutinib plus obinutuzumab in patients with relapsed/refractory CLL in the trial and how the results could result in another treatment option for patients with relapsed/refractory CLL.

SHR3680 Plus ADT Improves Survival Vs Bicalutamide/ADT in High-Volume mHSPC

July 27th 2022

The addition of SHR3680 to androgen deprivation therapy significantly improved radiographic progression-free survival and overall survival compared with bicalutamide plus ADT in patients with high-volume, metastatic hormone-sensitive prostate cancer, according to data from the phase 3 CHART trial.

IRX-2 Immunotherapy Misses EFS End Point in Newly Diagnosed Head and Neck Cancer

July 27th 2022

IRX-2 failed to demonstrate a statistically significant improvement in event-free survival as neoadjuvant therapy compared with standard of care in patients with newly diagnosed, stage II, III, or IVA squamous cell carcinoma of the oral cavity.

Direct Partnership With Patients May Accelerate Cancer Research and Precision Oncology

July 27th 2022

During the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.

LAG-3 Fills a Complex Role in the Immune System

July 27th 2022

The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.